HER2-Directed Advances in Lung Cancer
Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.
Good evening and welcome! Thank you for joining OncLive’s second episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year.
Live from New York City, I’m Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, at Mount Sinai, and it’s great to be back on this program, this time as your host!
But it’s not just me tonight. Virtually joining me tonight is Isabel Preeshagul, DO, MBS, a medical oncologist at Memorial Sloan Kettering Cancer Center, and Joshua K. Sabari, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine.
Tonight’s discussion is going to focus on some really interesting data and exciting breakthroughs regarding targeted therapies in lung cancer, some of which was presented at the 2020 World Conference on Lung Cancer, as well as some take-home messages about the current state of molecular testing, especially in the community setting.
Funding provided by Daiichi Sankyo/Content Developed Independently by OncLive
